Hematologic Oncology Update cover image

Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition

Hematologic Oncology Update

00:00

The Benefits of a Caliber BTK Inhibitor

The one thing that a caliber may have, and its advantage is the hypertension signal. We saw slightly lower rates of hemorrhage and bruising bleeding in the elevate study comparatively to Xanabrutin. But again, this is where these kind of indirect comparison studies with common denominators, roll arms are going to be valuable because we may never see these true head to head Cala versus Xanu study ever.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app